首页|纳米生物材料标准化检测和评价的现状与展望

纳米生物材料标准化检测和评价的现状与展望

扫码查看
近年来,纳米生物材料被广泛应用于药物靶向递送、医学成像、组织工程、生物传感、化妆品等生物医学领域.纳米材料的特殊性质使其在提高材料性能的同时也带来潜在的生物安全性风险.目前,我国的纳米科技水平已处于世界前沿,然而纳米技术的转化仍旧是短板.纳米生物材料要实现生物医药产品的转化应用,围绕"质量控制"和"安全性评估"两个主要方面,尚有很多关键问题急需解决.本文将综述纳米生物材料及其产品的理化性质表征和生物安全性评价的标准化现状、存在的问题及发展趋势等,为纳米生物材料的转化应用提供参考.
Research progress and prospects of standardized testing and assessment for nanobiomaterials
Nanobiomaterials,as nanotechnology-derived biomaterials,are referred to those biomaterials whose structures or components exhibit novel and significantly changed properties when their dimensions are at the nanoscale(1-100 nm).Hence,due to the unique features,nanobiomaterials have been extensively applied to targeted drug delivery,medical imaging,tissue engineering,biosensing as well as cosmetics over the past few decades.Meanwhile,the new characteristics of nanobiomaterials can also bring potential risks in biological safety together with performance.Currently,China has played a large role in the development of nanoscience and nanotechnology in the world in quite a lot of benefits related fields since there are the most abundant nano-related publications.Additionally,since National Technical Committee 279 on Nanotechnology of Standardization Administration of China was founded in 2005,China has released more than 100 national standards in the field of nanobiomaterials and over 30 related national standard plans are under development.Moreover,the industry standards for medical devices containing nanomaterials in China have been vigorously pushed forward.In the past China tended to publish scientific papers for original research,but now analytic data have shown an exponential growth in the nanobiomaterials related patents,about more than 1700 cases.However,nanotechnology translation is far behind in our country.There are very few real nano-products in the biomedical field.As for the translation from nanobiomaterials to biomedical applications,there are still so many critical issues which need to be addressed urgently,mainly including quality control and biosafety evaluation.The major challenges consist in the accurate measurement of physicochemical properties for nanobiomaterials and the setup of nano-biosafety knowledge system.Although some advanced techniques can give a valuable understanding of nanobiomaterials,especially for some special scenarios involving the presence of nanobiomaterials in complex matrices to confirm nano-content labeling as well as nanobiomaterial release from medical devices and so on.The repeatability and applicability of these measurements based on advanced techniques are still limited so far,which can be improved by standardized testing.In addition,there is still a lack of standardized biological assays as well as experimental animal models for biosafety evaluation.Standardization is the bridge of innovation-driven development as an indispensable way to achieving the repeatability and reproducibility of new technologies and large-scale production.It can also push the marketization and internationalization of these new advanced technologies and be very helpful to promote China transformation from"Made in China"to"Chinese Standards".Therefore,the standardized testing will definitely provide much more accurate and reliable information regarding the characterization of physicochemical properties and risk-benefit evaluation of nanobiomaterials.In order to offer a strong support and reference for nanobiomaterial development and nanotechnology translation in our country,this review summarizes the current situation of standardized testing,existing issues and development trend of physicochemical characterization and biosafety evaluation for nanobiomaterials as well as the related products.As new strategic and cutting-edge materials around the world,the development and application of nanobiomaterials will be bound to further improve the overall medical efficiency and support the national strategy of healthy in China in the future.

nanobiomaterialsstandardphysicochemical characterizationbiosafety evaluationconversion

刘颖、吴美玉、刘伊、高洁、王孝平、陈宽、文海若、陈亮、邵安良、肖百全、葛广路、谢黎明

展开 >

国家纳米科学中心,中国科学院纳米生物效应与安全性重点实验室,北京 100190

国家纳米科学中心,中国科学院纳米标准与检测重点实验室,北京 100190

国家纳米科学中心,标准认可战略部,北京 100190

国家纳米科学中心,纳米技术发展部,北京 100190

国家药品监督管理局,医疗器械技术审评中心,北京 100081

中国食品药品检定研究院,国家药物安全评价监测中心,药物非临床安全评价研究北京市重点实验室,北京 100176

中国食品药品检定研究院,医疗器械检定所,北京 102629

广东粤港澳大湾区国家纳米科技创新研究院,广州 510700

展开 >

纳米生物材料 标准 理化表征 生物安全性评价 转化

国家重点研发计划中国科学院战略性先导科技专项(B类)

2022YFC2409700XDB36020200

2023

科学通报
中国科学院国家自然科学基金委员会

科学通报

CSTPCDCSCD北大核心
影响因子:1.269
ISSN:0023-074X
年,卷(期):2023.68(32)
  • 1
  • 4